Nkarta to Participate in Needham Virtual Healthcare Conference

Rhea-AI Summary

Nkarta (Nasdaq: NKTX) will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. CEO Paul Hastings will join a panel at 11:45 a.m. ET on “Cell Therapy in Autoimmune.” President Nadir Mahmood will deliver a fireside chat at 3:45 p.m. ET covering updates on Nkarta’s investigational CAR-NK therapy for B cell-mediated autoimmune diseases. A simultaneous webcast of the fireside chat will be available on the company’s Investors website, with a replay archived for approximately 90 days.

News Market Reaction – NKTX

+1.30%

11 alerts

+1.30% Session close to close

-4.4% Trough in 2 hr 26 min

$158.86M Market Cap

0.8x Rel. Volume

In the Apr 9 session, NKTX gained 1.30%, reflecting a mild positive market reaction. Argus tracked a trough of -4.4% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Nkarta’s continued participation in high-visibility healthcare conferen...

Analysis

This announcement highlights Nkarta’s continued participation in high-visibility healthcare conferences, featuring a panel and fireside chat on its engineered NK and CAR-NK programs in autoimmune disease. Historically, similar conference updates have led to modest, aligned price moves rather than major dislocations. Investors may watch for any incremental scientific or pipeline commentary emerging from the Needham event, while keeping in mind the recently established $350,000,000 Form S-3 shelf and $100,000,000 ATM program.

Key Figures

Panel time: 11:45 a.m. ET Fireside chat time: 3:45 p.m. ET Conference edition: 25th Annual +1 more

4 metrics

Panel time 11:45 a.m. ET Virtual panel on April 15, 2026 at Needham conference

Fireside chat time 3:45 p.m. ET Afternoon Nkarta fireside chat at Needham conference

Conference edition 25th Annual Needham Virtual Healthcare Conference iteration

Webcast replay period 90 days Archived replay of fireside chat on Nkarta’s investor website

Historical Context

5 past events · Latest: Mar 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 25	Earnings and update	Positive	+0.5%	Reported FY 2025 results and cash runway into 2029 with NKX019 progress.
Feb 27	Investor conferences	Neutral	+3.0%	Announced March 2026 fireside chats at TD Cowen and Leerink conferences.
Dec 02	Conference appearance	Neutral	-3.9%	Planned Evercore 8th Annual Healthcare Conference fireside chat and webcast.
Nov 10	Earnings and clinical	Positive	+2.5%	Q3 2025 results, NKX019 autoimmune program updates, and complete B-cell depletion data.
Oct 30	Investor conferences	Neutral	-0.5%	Announced November 2025 Stifel and TD Cowen conference fireside chats with webcasts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news—mainly earnings and conference participation—has produced modest, generally aligned price moves, with no strong negative reactions.

Recent Company History

Over the last six months, Nkarta has combined financial updates with steady visibility efforts. On Nov 10, 2025, Q3 results and NKX019 progress coincided with a 2.55% gain. The Dec 4, 2025 and Nov 2025 conference participations saw small moves around fireside chats and investor outreach. On Mar 25, 2026, Q4/FY 2025 results highlighted $295.1 million in cash funding operations into 2029, with a mild 0.47% rise. Prior conference-related news in Feb 2026 produced a slightly stronger 3.05% gain.

Key Terms

natural killer (nk) cell therapies, car-nk cell therapy, b cell-mediated autoimmune diseases

3 terms

natural killer (nk) cell therapies medical

"a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies"

Natural killer (NK) cell therapies use a type of immune cell that can find and destroy diseased cells — such as cancer — either after being grown and boosted outside the body or after being modified to work better. Investors care because these therapies represent a growing class of targeted treatments with the potential for high clinical benefit and commercial value, but they also carry scientific and regulatory risk similar to other advanced biotechnologies.

car-nk cell therapy medical

"investigational CAR-NK cell therapy to treat B cell-mediated autoimmune diseases"

CAR-NK cell therapy uses a patient's or donor immune cells called natural killer (NK) cells that are genetically equipped with a targeting receptor (CAR) to find and destroy cancer cells. Think of it as giving trained guard dogs a custom scent to track intruders; the approach can be faster to deploy and potentially safer than some other cell therapies. Investors care because successful CAR-NK programs can drive clinical trial milestones, regulatory approvals, and scalable product models that affect company value and future revenue.

b cell-mediated autoimmune diseases medical

"CAR-NK cell therapy to treat B cell-mediated autoimmune diseases"

B cell-mediated autoimmune diseases are conditions in which a type of immune cell called a B cell makes antibodies that mistakenly attack the body’s own tissues, like a security guard turning on the people it's supposed to protect. For investors, these diseases matter because they drive demand for drugs and diagnostics, shape clinical trial design and regulatory risk, and can determine revenue potential and competition in the biotech and pharmaceutical markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference.

At 11:45 a.m. ET on Wednesday, April 15, Nkarta CEO Paul Hastings will participate in a virtual panel discussion, “Cell Therapy in Autoimmune: State of the Art and What Comes Next.”

Later that afternoon, Nkarta President Nadir Mahmood will participate in a 3:45 p.m ET fireside chat to share updates on the company’s investigational CAR-NK cell therapy to treat B cell-mediated autoimmune diseases.

A simultaneous webcast of the fireside chat will be available on the Investors section of Nkarta’s website, and a replay will be archived on the website for approximately 90 days.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Nadir Mahmood
Nkarta, Inc.
nmahmood@nkartatx.com

FAQ

When will Nkarta (NKTX) present at the Needham Virtual Healthcare Conference on April 15, 2026?

Nkarta will present on April 15, 2026 with two scheduled appearances during the virtual conference. According to the company, CEO Paul Hastings speaks at 11:45 a.m. ET and President Nadir Mahmood at 3:45 p.m. ET.

How can investors watch Nkarta's (NKTX) fireside chat at the Needham conference?

Investors can watch the fireside chat via a simultaneous webcast on Nkarta's Investors website. According to the company, the live webcast will be posted and a replay archived on the site for about 90 days.

What topics will Nkarta (NKTX) cover at the Needham Virtual Healthcare Conference?

Nkarta will discuss cell therapy approaches for autoimmune disease and its CAR-NK program for B cell-mediated conditions. According to the company, the sessions include a panel on Cell Therapy in Autoimmune and a fireside chat with program updates.

Who from Nkarta (NKTX) will speak at the Needham Virtual Healthcare Conference?

Nkarta's CEO Paul Hastings and President Nadir Mahmood will speak on April 15, 2026 at the virtual conference. According to the company, Hastings joins a panel and Mahmood leads a 3:45 p.m. ET fireside chat.

Will a replay of Nkarta's (NKTX) Needham presentation be available after the conference?

Yes. A replay of the fireside chat will be archived on Nkarta's Investors website for approximately 90 days. According to the company, the replay will be accessible following the live event for investor review.